Skip to main content

Table 1 Patient characteristics

From: Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors

 

Step 1

Step 2

(n = 22)

(n = 15)

Sex, Male

15 (68)

13 (87)

Age, year (mean [range])

68 (56–78)

66 (49–76)

Weight, kg (mean [range])

55 (40–85)

55 (42–70)

Height, cm (mean [range])

162 (148–178)

165 (160–173)

Cancer typea

 Gastric

16 (73)

9 (60)

 Esophageal

4 (18)

6 (40)

 Colorectal

1 (5)

0 (0)

 NSCLC

2 (9)

0 (0)

 Thyroid

1 (5)

0 (0)

Primary tumor

 Present

11 (50)

8 (53)

Prior cancer therapy

 Chemotherapy

22 (100)

15 (100)

  No. of regimens (mean [range])

4.4 (2–7)

4.5 (2–8)

 Surgery

10 (46)

8 (53)

 Radiation

3 (14)

4 (27)

EPHA2 expressionb

 0

10 (46)

0 (0)

 1+

2 (9)

0 (0)

 2+

6 (27)

13 (87)

 3+

1 (5)

2 (13)

  1. N (%) unless otherwise stated
  2. Abbreviations: NSCLC, non–small-cell lung cancer; EPHA2, erythropoietin-producing hepatocellular receptor A2
  3. aPatients with more than one type of cancer were repeatedly counted
  4. bData were presented only for patients who have been examined for EPHA2 expression
Back to article page